Pfizer Inc


Want a discount? Become a member by purchasing Annual Subscription!
SKU: PFE-1 Category:


Pfizer is one of the largest pharmaceutical companies in the world by market capitalization and has gained a lot of steam over the past few quarters given its success on the Covid-19 vaccine front. While its revenue growth from the past few years was relatively slow on account of the sale of its consumer healthcare business as well as its generic drugs business, there is a robust upside expected from the success of many of its key drugs such as Ibrance, Vyndaqel, Eliquis, Xeljanz, and Vyndaqel. The company should continue to have a positive 2021 on account of the success of these drugs coupled with the robust demand for its Covid-19 vaccine which is expected to be sustainable in the long term. For yield players, Pfizer is a reliable blue chip that offers decent dividend payouts. The company has a strong pipeline in oncology as well as Covid-19 and deserves a ‘Hold’ rating.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!